Artel’s Acquisition by Advanced Instruments
April 26, 2022
On April 26, 2022, Artel, a global leader in low volume liquid delivery measurement and quality assurance used throughout the life science industry, and Advanced Instruments, a leading manufacturer of analytical instruments and services for the clinical, biopharmaceutical and food & beverage sectors, announced the execution of a definitive agreement for Advanced Instruments to acquire Artel. Cravath is representing Artel in connection with the transaction.
The Cravath team includes associates Richard E. Schwartz and Armin Hoss on M&A matters; senior attorney Kiran Sheffrin and associate Duncan H. Hardell on tax matters; partner Eric W. Hilfers and associates Anna Mikaelyan and Molly E. Nichols on executive compensation and benefits matters; partner David J. Kappos and associate Pedraam Mirzanian on intellectual property matters; practice area attorney Nicole M. Peles and associate Stijn de Jong on regulatory matters; senior attorney Annmarie M. Terraciano on environmental matters; and practice area attorney Brian M. Budnick on real estate matters.
Related Practices & Industries
People
- Photo
-
-
J.D., 1998, University of Chicago Law Schoolwith Honors
-
A.B., 1995, Princeton University
- New York
Education
Admitted In
- Photo
-
-
J.D., 1990, University of California, Berkeley, School of Law
-
B.S., 1983, University of California, Davissumma cum laude
- New York
- California
- District of Columbia
Education
Admitted In
- Photo
-
-
J.D., 2010, New York University School of Lawcum laude
-
A.B., 2007, Dartmouth College
- New York
Education
Admitted In
- Photo
-
-
J.D., 1998, Columbia Law SchoolHarlan Fiske Stone Scholar
-
M.S., 1994, University of Wisconsin - Madison
-
B.A., 1989, Wellesley Collegecum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 2011, Benjamin N. Cardozo School of Lawcum laude
-
B.A., 2006, University of Virginia
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
March 31, 2026
Biogen’s $5.6 Billion Acquisition of Apellis
On March 31, 2026, Biogen Inc. and Apellis Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire all outstanding shares of Apellis for $41.00 per share in cash at closing, or approximately $5.6 billion. Apellis stockholders will also receive a nontransferable CVR for each Apellis share held, entitling the holder to receive two payments of $2 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE®. Cravath is representing Biogen in connection with the transaction.
Deals & Cases
March 09, 2026
Talkspace’s Acquisition by UHS
On March 9, 2026, Universal Health Services, Inc. (“UHS”) announced that it has entered into a definitive agreement to acquire Talkspace, Inc. (“Talkspace”) for $5.25 per share. The enterprise value for the transaction is approximately $835 million. Cravath is representing Talkspace in connection with the transaction.
Deals & Cases
February 18, 2026
Tenax’s Merger with Air
On February 17, 2026, Tenax Aerospace Acquisition, LLC (“Tenax”) and Air Industries Group (“Air”) jointly announced that they have entered into an Agreement and Plan of Merger to combine Tenax’s special mission aviation business with Air’s precision aerospace manufacturing business. At the time of the merger, Air will issue shares of its common stock to holders of Tenax membership units. After the closing, Tenax shareholders are expected to own approximately 95% of Air’s outstanding shares while existing Air shareholders are expected to own approximately 5%, and the combined company expects to remain listed on the NYSE American under the symbol AIRI. Cravath is representing Tenax in connection with the transaction.
Deals & Cases
February 17, 2026
Kennedy Wilson’s Acquisition by Consortium Led by William McMorrow and Fairfax
On February 17, 2026, Kennedy‑Wilson Holdings, Inc. (“Kennedy Wilson”) and Fairfax Financial Holdings Limited (“Fairfax”) jointly announced that Kennedy Wilson has entered into a definitive agreement to be acquired, in an all cash‑transaction, by an entity affiliated with a consortium led by William McMorrow, Chairman and Chief Executive Officer of Kennedy Wilson, and certain other senior executives of Kennedy Wilson (collectively, the “KW Management Group”), together with Fairfax (collectively, the “Consortium”).
